Newsroom

/Newsroom/

Update on a New Clinical Trial Offered to Eligible GIST Patients

Deciphera Pharmaceuticals is testing an investigational drug called ripretinib (DCC-2618) as a potential new treatment option for patients living with GIST. About Ripretinib Ripretinib is an oral investigational drug designed to treat GISTs that [...]

By |2019-06-20T14:58:27-04:00June 20th, 2019|Clinical Trials, News, Newsletter|

One Voice Against Cancer (OVAC) Advocates for Cancer Patients

OVAC is a coalition of over 50 nonprofit cancer organizations that advocate on behalf of cancer patients to deliver a unified message to Congress and to the White House on the need for increased [...]

By |2019-07-02T14:28:52-04:00June 20th, 2019|Advocacy, News, Newsletter|

Stepping into Personalized Side Effect Management with SideEQ

What Can SideEQ Do for You? What is personalized side effect management, and why is it important for your survival and quality of life? “Never judge a person until you’ve walked a mile in [...]

By |2019-06-20T11:37:27-04:00June 20th, 2019|News, Newsletter, Side Effects|

Recent Posts

Upcoming Events

  1. SPAEN hosts webcast by Dr. Trent

    Novel Treatments in GIST

    July 24 @ 2:00 PM
  2. LRG Webcast Series: When to Consider Surgery

    August 8 @ 2:00 PM - 3:00 PM
  3. GDOL Ottawa logo

    GIST Day of Learning – Ottawa

    September 28 @ 9:00 AM - 4:30 PM